WALTHAM, Massachusetts - a history of 28 April on the immunogenic third quarter revenues, the Associated Press reported that immunogenic wrongly licensed trastuzumab rock emtansine. Immunogenic licensed the technology used in the drug to the rock.
The story did not also make clear that emtansine trastuzumab trastuzumab, which is marketed as Herceptin, combines technology with murder of immunogenic cancer cell DM1.
In addition to the clinical trial result, Roche/Genentech runs a clinical study of late phase of trastuzumab emtansine as a primary treatment for breast cancer.
Trastuzumab emtansine is being studied as a treatment for the breast cancer HER2 positive, a more aggressive type of disease that is less sensitive to hormonal treatments.
No comments:
Post a Comment